9c8140ab-454c-4f62-aa6e-d1cfe4e498e0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 47
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.430
- OXIDATIVE_PHOSPHORYLATION+0.400
- MYC_TARGETS_V2+0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- MYOGENESIS+0.360
- COAGULATION+0.340
- DNA_REPAIR+0.300
- INTERFERON_ALPHA_RESPONSE+0.280
- PANCREAS_BETA_CELLS+0.260
- XENOBIOTIC_METABOLISM+0.260
Top 10 suppressed
- ANDROGEN_RESPONSE-0.370
- PROTEIN_SECRETION-0.360
- G2M_CHECKPOINT-0.350
- MITOTIC_SPINDLE-0.330
- UV_RESPONSE_DN-0.330
- E2F_TARGETS-0.260
- TGF_BETA_SIGNALING-0.240
- HEME_METABOLISM-0.150
- TNFA_SIGNALING_VIA_NFKB-0.140
- KRAS_SIGNALING_UP-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG482 | — | — | 0.819 |
| 2 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.814 |
| 3 | 966a66a2-8aac-41e8-8007-88fd92d2e8e8 | — | — | 0.804 |
| 4 | SRR25043613 | — | — | 0.798 |
| 5 | MDT-AP-2585 | Med | Medulloblastoma | 0.793 |
| 6 | b83a1cf6-50a6-44fa-834d-8b3df88149fa | — | — | 0.785 |
| 7 | 131e315e-6653-4199-b653-42b81644dad9 | — | — | 0.783 |
| 8 | f0f41799-29e8-43f9-b357-722df163e963 | — | — | 0.769 |
| 9 | 47661ed9-5c0e-442d-b072-3da8b14fab02 | — | — | 0.760 |
| 10 | b2b53efa-8a7b-4871-b6bb-6ebfb5cc0cea | — | — | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.120 | Idelalisib | — uncovered |